{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:47:33Z","timestamp":1776739653948,"version":"3.51.2"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpedsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Surgery"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jpedsurg.2023.02.017","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T11:57:08Z","timestamp":1676635028000},"page":"1145-1154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma"],"prefix":"10.1016","volume":"58","author":[{"given":"Laura V.","family":"Bownes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet R.","family":"Julson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin H.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Claire","family":"Hutchins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Erwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooper R.","family":"Markert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry E.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Mroczek-Musulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Aye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina J.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ohlmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-0527","authenticated-orcid":false,"given":"Elizabeth A.","family":"Beierle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpedsurg.2023.02.017_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40880-019-0411-7","article-title":"Incidence trends and survival prediction of hepatoblastoma in children: a population-based study","volume":"39","author":"Feng","year":"2019","journal-title":"Cancer Commun"},{"issue":"3","key":"10.1016\/j.jpedsurg.2023.02.017_bib2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MOP.0000000000000081","article-title":"Management of hepatoblastoma: an update","volume":"26","author":"Kremer","year":"2014","journal-title":"Curr Opin Pediatr"},{"issue":"10","key":"10.1016\/j.jpedsurg.2023.02.017_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12676","article-title":"Assessment of survival of pediatric patients with hepatoblastoma who received chemotherapy following liver transplant or liver resection","volume":"2","author":"Feng","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.jpedsurg.2023.02.017_bib4","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","article-title":"Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study","volume":"14","author":"Zsiros","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jpedsurg.2023.02.017_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2003.06.003","article-title":"Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2","volume":"40","author":"Perilongo","year":"2004","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jpedsurg.2023.02.017_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.molonc.2015.01.002","article-title":"Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer","volume":"9","author":"Chien","year":"2015","journal-title":"Mol Oncol"},{"issue":"6","key":"10.1016\/j.jpedsurg.2023.02.017_bib7","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1172\/JCI89548","article-title":"Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth","volume":"127","author":"Sangodkar","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.jpedsurg.2023.02.017_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125693","article-title":"Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma","volume":"4","author":"Tohm\u00e9","year":"2019","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.jpedsurg.2023.02.017_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214469","article-title":"PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells","volume":"14","author":"Stafman","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jpedsurg.2023.02.017_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tranon.2018.09.011","article-title":"Investigation of PP2A and its endogenous inhibitors in neuroblastoma cell survival and tumor growth","volume":"12","author":"Williams","year":"2019","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.jpedsurg.2023.02.017_bib11","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1038\/s41598-018-25263-5","article-title":"FTY720 decreases yumorigenesis in group 3 medulloblastoma patient-derived xenografts","volume":"8","author":"Garner","year":"2018","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.jpedsurg.2023.02.017_bib12","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2013-03-492181","article-title":"Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies","volume":"122","author":"Oaks","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jpedsurg.2023.02.017_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa002","article-title":"Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma","volume":"2","author":"Merisaari","year":"2020","journal-title":"Brain Commun"},{"issue":"8","key":"10.1016\/j.jpedsurg.2023.02.017_bib14","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.3390\/cancers14081952","article-title":"Pre-clinical study evaluating novel protein phosphatase 2A activators as therapeutics for neuroblastoma","volume":"14","author":"Bownes","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jpedsurg.2023.02.017_bib15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1593\/tlo.12505","article-title":"FAK inhibition decreases hepatoblastoma survival both in vitro and in vivo","volume":"6","author":"Gillory","year":"2013","journal-title":"Transl Oncol"},{"issue":"32","key":"10.1016\/j.jpedsurg.2023.02.017_bib16","doi-asserted-by":"crossref","first-page":"22665","DOI":"10.18632\/oncotarget.25205","article-title":"Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma","volume":"9","author":"Stafman","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.jpedsurg.2023.02.017_bib17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"issue":"13","key":"10.1016\/j.jpedsurg.2023.02.017_bib18","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.3390\/cancers13133201","article-title":"Serine-threonine kinase receptor-associated protein (STRAP) knockout decreases the malignant phenotype in neuroblastoma cell lines","volume":"13","author":"Bownes","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jpedsurg.2023.02.017_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100893","article-title":"9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts","volume":"14","author":"Marayati","year":"2021","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.jpedsurg.2023.02.017_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/abio.1999.4085","article-title":"Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro","volume":"270","author":"Winer","year":"1999","journal-title":"Anal Biochem"},{"issue":"5","key":"10.1016\/j.jpedsurg.2023.02.017_bib21","first-page":"523","article-title":"The welfare of animals used in science: how the \"Three Rs\" ethic guides improvements","volume":"50","author":"Fenwick","year":"2009","journal-title":"Can Vet J"},{"issue":"3","key":"10.1016\/j.jpedsurg.2023.02.017_bib22","first-page":"69","article-title":"A\u00a0note on error bars as a graphical representation of the variability of data in biomedical research: choosing between standard deviation and standard error of the mean","volume":"2","author":"Tang","year":"2019","journal-title":"J\u00a0Pancreatol"},{"key":"10.1016\/j.jpedsurg.2023.02.017_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ebiom.2018.12.032","article-title":"Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression","volume":"40","author":"Liu","year":"2019","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.jpedsurg.2023.02.017_bib24","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.3892\/or.2016.4668","article-title":"FTY720-induced enhancement of autophagy protects cells from FTY720 cytotoxicity in colorectal cancer","volume":"35","author":"Li","year":"2016","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.jpedsurg.2023.02.017_bib25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1535-7163.MCT-13-0150","article-title":"PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential","volume":"13","author":"Crist\u00f3bal","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.jpedsurg.2023.02.017_bib26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrc.2018.15","article-title":"Cell motility in cancer invasion and metastasis: insights from simple model organisms","volume":"8","author":"Stuelten","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"46","key":"10.1016\/j.jpedsurg.2023.02.017_bib27","doi-asserted-by":"crossref","first-page":"35567","DOI":"10.1074\/jbc.M607702200","article-title":"Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains","volume":"281","author":"Xu","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.jpedsurg.2023.02.017_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11596-018-1854-9","article-title":"PP2A inhibits cervical cancer cell migration by dephosphorylation of p-JNK, p-p38 and the p-ERK\/MAPK signaling pathway","volume":"38","author":"Zheng","year":"2018","journal-title":"Curr Med Sci"},{"issue":"3","key":"10.1016\/j.jpedsurg.2023.02.017_bib29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.trsl.2014.07.009","article-title":"Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data","volume":"165","author":"Bahnassy","year":"2015","journal-title":"Transl Res"},{"issue":"3","key":"10.1016\/j.jpedsurg.2023.02.017_bib30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1541-7786.MCR-17-0393","article-title":"Stemness is enhanced in gastric cancer by a SET\/PP2A\/E2F1 axis","volume":"16","author":"Enjoji","year":"2018","journal-title":"Mol Cancer Res"},{"issue":"14","key":"10.1016\/j.jpedsurg.2023.02.017_bib31","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.3390\/ijms22147259","article-title":"FTY720 Inhibits expansion of breast cancer stem cells via PP2A activation","volume":"22","author":"Hirata","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jpedsurg.2023.02.017_bib32","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1038\/s41598-021-85289-0","article-title":"PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma","volume":"11","author":"Marayati","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jpedsurg.2023.02.017_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3349\/ymj.2018.59.1.35","article-title":"Correlation of cancer stem-cell markers OCT4, SOX2, and NANOG with clinicopathological features and prognosis in operative patients with rectal cancer","volume":"59","author":"You","year":"2018","journal-title":"Yonsei Med J"},{"issue":"6","key":"10.1016\/j.jpedsurg.2023.02.017_bib34","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jpedsurg.2021.02.041","article-title":"Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenografts","volume":"56","author":"Marayati","year":"2021","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.jpedsurg.2023.02.017_bib35","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.2147\/OTT.S173522","article-title":"OCT4, SOX2, and NANOG positive expression correlates with poor differentiation, advanced disease stages, and worse overall survival in HER2(+) breast cancer patients","volume":"11","author":"Yang","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.jpedsurg.2023.02.017_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fped.2016.00022","article-title":"Hepatoblastoma: a need for cell lines and tissue banks to develop targeted drug therapies","volume":"4","author":"Rikhi","year":"2016","journal-title":"Front Pediatr"},{"issue":"Suppl 2","key":"10.1016\/j.jpedsurg.2023.02.017_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/annonc\/4.suppl_2.S7","article-title":"Stereoisomers in clinical oncology: why it is important to know what the right and left hands are doing","volume":"4","author":"Wainer","year":"1993","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jpedsurg.2023.02.017_bib38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00007691-199312000-00021","article-title":"Stereoselective separations of chiral anticancer drugs and their application to pharmacodynamic and pharmacokinetic studies","volume":"15","author":"Wainer","year":"1993","journal-title":"Ther Drug Monit"},{"issue":"11","key":"10.1016\/j.jpedsurg.2023.02.017_bib39","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.3390\/molecules26113113","article-title":"Enantioselectivity in drug pharmacokinetics and toxicity: pharmacological relevance and analytical methods","volume":"26","author":"Coelho","year":"2021","journal-title":"Molecules"},{"issue":"51","key":"10.1016\/j.jpedsurg.2023.02.017_bib40","doi-asserted-by":"crossref","first-page":"84214","DOI":"10.18632\/oncotarget.12394","article-title":"Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia","volume":"7","author":"Richard","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jpedsurg.2023.02.017_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/emmm.201201283","article-title":"Sphingosine analogue drug FTY720 targets I2PP2A\/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis","volume":"5","author":"Saddoughi","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"22","key":"10.1016\/j.jpedsurg.2023.02.017_bib42","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/onc.2010.622","article-title":"Targeting SET\/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy","volume":"30","author":"Switzer","year":"2011","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.jpedsurg.2023.02.017_bib43","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1158\/0008-5472.CAN-13-1994","article-title":"Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target","volume":"73","author":"Khanna","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jpedsurg.2023.02.017_bib44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","article-title":"CIP2A inhibits PP2A in human malignancies","volume":"130","author":"Junttila","year":"2007","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.jpedsurg.2023.02.017_bib45","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1158\/0008-5472.CAN-20-3651","article-title":"CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis","volume":"81","author":"Laine","year":"2021","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jpedsurg.2023.02.017_bib46","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41419-022-04848-z","article-title":"Mechanism of cancer stemness maintenance in human liver cancer","volume":"13","author":"Liang","year":"2022","journal-title":"Cell Death Dis"},{"issue":"9","key":"10.1016\/j.jpedsurg.2023.02.017_bib47","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood.2020010344","article-title":"PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc\/p21 axis in human and murine acute myeloid leukemia","volume":"139","author":"Goswami","year":"2022","journal-title":"Blood"}],"container-title":["Journal of Pediatric Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022346823001379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022346823001379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T08:45:24Z","timestamp":1758357924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022346823001379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0022346823001379"],"URL":"https:\/\/doi.org\/10.1016\/j.jpedsurg.2023.02.017","relation":{},"ISSN":["0022-3468"],"issn-type":[{"value":"0022-3468","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpedsurg.2023.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}